Mind Medicine (MindMed) Inc MNMD

Alternate Symbol(s): N.MMED.WS | N.MMED.WA | N.MMED.WR | N.MMED

Healthcare

Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates. MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that it is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).

NDAQ:MNMD - Post by User

Mind Medicine (MindMed) Inc > LSD-25

<< Previous

Bullboard Posts

Next >>

Post by maoae7on Jan 26, 2022 7:17am

415 Views

Post# 34361208

LSD-25

Anybody here have tried LSD? Do you know what you are invested in? I can get LSD micro-dosing easily. Why should i bother with MindMed? In the sixties the psychiatrist Stanislas Grof tested LSD with 3,500 patients and it was not conclusive. Is MindMed trying to get a "patent" on LSD? The molecule is extracted from a toxic mushroom(ergot) found on Rye mostly.. I bought at .40 and i am out.

<< Previous

Bullboard Posts

Next >>

BMO evolves InvestorLine with enhanced tools for options trading